The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 28, 2020

Filed:

Dec. 02, 2015
Applicant:

Proclara Biosciences, Inc., Cambridge, MA (US);

Inventors:

Rajaraman Krishnan, Ashland, MA (US);

Eva Asp, Newton, MA (US);

Ming Proschitsky, Winchester, MA (US);

Richard Fisher, Cambridge, MA (US);

Francis J. Carr, Balmedie, GB;

Robert G. E. Holgate, Royston, GB;

Timothy D. Jones, Babraham, GB;

Assignee:

Proclara Biosciences, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/16 (2006.01); C07K 14/005 (2006.01); A61K 9/00 (2006.01); A61K 38/17 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/162 (2013.01); A61K 9/0019 (2013.01); A61K 38/1716 (2013.01); C07K 14/005 (2013.01); A61K 38/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/30 (2013.01); C12N 2795/14022 (2013.01);
Abstract

The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.


Find Patent Forward Citations

Loading…